Gremlin: vexing VEGF receptor agonist

Slides:

Advertisements

Similar presentations

Pathogenesis beyond the cancer clone(s) in multiple myeloma by Giada Bianchi, and Nikhil C. Munshi Blood Volume 125(20): May 14, 2015 ©2015 by.

Advertisements

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,

Why not the liver instead of the kidney?

Gene therapy: efficient targeting of hematopoietic stem cells

Uncontrolled Wnt signaling causes leukemia

The beauty of TLR agonists for CTCL

GVHD-associated immunodeficiency: soil or seed?

CD146: a new partner for VEGFR2

Hydroxyurea makes inflammation “just right”?

VEGF therapy: risky business for established plaques?

EBV DNA: a Hodgkin lymphoma biomarker?

TCR-MHC-peptide(s): in vivo veritas

“Vitamin hypothesis”: explanation for allergy increase?

Triple play of H pylori in ITP

Multiple Myeloma: Interleukin-15 Antagonizes Bone Morphogenetic Protein-Induced Apoptosis and Growth Inhibition. by Magne Rekvig, Anne-Tove Brenne, Torstein.

Neonatal GATA1 mutant clones under the radar

VEGF-D: a modifier of embryonic lymphangiogenesis

Another Notch on the belt

Inflammatory Reactivation and Angiogenicity of Kaposi’s Sarcoma-Associated Herpesvirus/HHV8: A Missing Link in the Pathogenesis of Acquired Immunodeficiency.

Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,

It's all in the timing by Linda J. Bendall Blood

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Angiopoietin-2 in CLL by Jan A. Burger Blood Volume 116(4):

BTK inhibition in myeloma: targeting the seed and the soil

Types of Tumor Vascularization

BRAF inhibitor: targeted therapy in hairy cell leukemia

Validation of the Nordic Scoring System for Erythropoietic Stimulating Agents in MDS Using IWG 2006 Erythroid Response Criteria by Jennifer Jayakar, Richard.

Inherited CalDAG-GEFI deficiency

V617F “JAKs” up myeloproliferative signal

FNAIT: the fetus pleads guilty!

T regulatory cells turn on T regulatory cells

Gnawing at Metchnikoff’s paradigm

Genetic sequence analysis of inherited bleeding diseases

Functional neutrophils from human ES cells

Targeting kinases in CML CLL

Deep mining of the RBC proteome

Has the T cell bitten off more than it can chew?

Basophils take a slice of IRF8 pie

Target recognition–induced NK-cell responses

Rare cells predict GVHD

Human CD27+IgM+IgD+ B cells: T-cell or TLR-dependent?

by Walter Zumkeller, and Stefan Burdach

ROCK and Rho(ll) in bone marrow

Ph+ ALL: drawing strength from a benign past

Latest lymphoma classification is skin deep

Lymphoma spread? Target CD47-SIRPα!

Chemokines and chemokine receptors: here, there, and everywhere

To the heart of the APS puzzle

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

Giulio Francia, Urban Emmenegger, Robert S. Kerbel Cancer Cell

Understanding the Importance of Smart Drugs in Renal Cell Carcinoma

A dual role of Erk signaling in embryonic stem cells

The Dual Role of Bone Morphogenetic Proteins in Cancer

The VEGF Family, the Inside Story

The Duality of Angiogenesis: Implications for Therapy of Human Disease

Blood and Marrow Transplant Handbook

by Christine L. Kempton, and Amanda B. Payne

Aggregation tracings of platelets lacking PLCβ2/β3.

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Schematic model of the mechanism of Tak1 protection of HSPC survival.

How I treat Burkitt lymphoma in adults

Anti-CD20-IL-21 fusokine: the tail wags the dog

Influence of the tumor microenvironment on FL

Overview of important signalling pathways in angiogenesis and antiangiogenic agents. Overview of important signalling pathways in angiogenesis and antiangiogenic.

A binding relationship with thrombin

by Kalpna Gupta, Chunsheng Chen, Gerard A. Lutty, and Robert P. Hebbel

Initial treatment of CLL: integrating biology and functional status

Chimeric antigen receptor–modified T cells: CD19 and the road beyond

A schematic diagram showing the mechanism by which L5 triggers platelet activation and aggregation. A schematic diagram showing the mechanism by which.

Presentation transcript:

Gremlin: vexing VEGF receptor agonist by Lena Claesson-Welsh Blood Volume 116(18):3386-3387 November 4, 2010 ©2010 by American Society of Hematology

Schematic outline of Gremlin's dual role in tumor biology. Schematic outline of Gremlin's dual role in tumor biology. Neutralization of BMPs may result in attenuation of suppressive signaling, whereas stimulation of VEGFR2 promotes angiogenesis. (Professional illustration by Marie Dauenheimer.)‏ Lena Claesson-Welsh Blood 2010;116:3386-3387 ©2010 by American Society of Hematology